mynth
04/2019Majority

Eurazeo takes majority stake in D.O.R.C.

NETHERLANDS Life Sciences / Medical Devices EV €300–700M

Context

Eurazeo Capital completed the acquisition of 100% of the share capital of D.O.R.C. from its previous owners. The transaction positions Eurazeo as the majority shareholder of a rapidly growing MedTech player in the dynamic ophthalmic surgery market. The strategic plan focuses on capitalizing on D.O.R.C.'s highly regarded brand and innovative technology to drive further international growth, with a specific priority on capturing market share in the US. Eurazeo also intends to support the company's shift towards a higher mix of recurring revenue through its proprietary consumables and surgical packs.

The acquisition of D.O.R.C. is part of the growth strategy of Eurazeo, which already has several external growth operations under its belt, notably Groupe CPK in 2017.

D.O.R.C., which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in the Netherlands, D.O.R.C. is a global leader in ophthalmic surgery equipment. It specializes in the "posterior segment" of the eye (vitreoretinal surgery). Its flagship product, the EVA Nexus platform, is a dual-function system used for both cataract and retina surgeries, highly regarded by surgeons for its precision.

Ent. Value

€300–700M

Equity Value

[members only]

Multiples

EV / Revenue

2x–6x

EV / EBITDA

[members only]

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2018
€100–200M
[members only]
[members only]
2017
€100–200M
[members only]
[members only]

Other operations with D.O.R.C.

Other operations with D.O.R.C.
DateAcquirerTargetCountrySector
08/2023CARL ZEISS MEDITECD.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)NETHERLANDSMedical Devices

Other operations with Eurazeo

Other operations with Eurazeo
DateAcquirerTargetCountrySector
10/2020EURAZEO / IK PARTNERS / RAISEQUESTEL GROUPFRANCEIndustry-Specific Software
09/2020EURAZEO / FCDE (FONDS DE CONSOLIDATION ET DE DEVELOPPEMENT DES ENTREPRISES)UTAC CERAMFRANCETIC (Testing, Inspection, Certification)
05/2017EURAZEOGROUPE CPK (CARAMBAR POULAIN KREMA)FRANCEFood Products
04/2016EURAZEO / MERIEUX EQUITY PARTNERSNOVACAPFRANCESpecialty Chemicals
03/2016EURAZEOGLION INSTITUTE / LES ROCHESSWITZERLANDEducation Providers
11/2015EURAZEOPLANET PAYMENTIRELANDFintech & Payments
09/2014EURAZEOCOLISÉEFRANCENursing Homes
03/2014EURAZEODESIGUALSPAINFashion & Apparel
02/2014EURAZEOVIGNAL GROUPFRANCEAuto Parts & Systems
01/2014EURAZEOASMODEE GROUPFRANCEConsumer Products

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
07/20193IIONISOSFRANCECDMO
05/2019ARDIANSINTETICASWITZERLANDPharma & Biotech
04/2019ICG / MERIEUX EQUITY PARTNERSDOC GENERICIITALYGenerics / Labs
12/2018MERCK & CO.ANTELLIQFRANCEAnimal Health
11/2018ARDIANNEOPHARMED GENTILIITALYGenerics / Labs
10/2018GLANBIASLIMFASTUNITED STATESNutrition & Dietary Supplements
10/2018ASTORGNEMERAFRANCEMedical Consumables
10/2018BRIDGEPOINTHTL BIOTECHNOLOGYFRANCECDMO
10/2018ARDIANINULA GROUPBELGIUMPharma & Biotech
08/2018DENTRESSANGLEACTEONFRANCEMedical Devices

REFERENCES

Valuation range: EV €300–700M

Revenue range: €100–200M

EV/Revenue range: 2x - 6x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of D.O.R.C. by Eurazeo are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in D.O.R.C., a Dutch company specialised in Medical Devices, by Eurazeo in 2019. Ownership has since evolved, leading to a subsequent transaction with Carl Zeiss Meditec in August 2023 (see the dedicated deal page for details).

How was the acquisition of D.O.R.C. by Eurazeo valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €300–700M band and its EV/revenue multiple within the 2x - 6x range. Exact figures are available to members.

What was D.O.R.C.’s revenue at the time of the deal?

At the time of the transaction, D.O.R.C.’s annual revenue was estimated within the €100–200M range (FY 2018). Detailed financial figures are available to members.

What sources support the information on this transaction?

The details of this transaction are sourced directly from the official corporate announcement published on the parties’ institutional website, ensuring primary-source verification of the closing and perimeter.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.